Tacrolimus to Sirolimus Conversion for Delayed Graft Function (RAPA)
Delayed Tacrolimus to Sirolimus Conversion in Renal Transplant Recipients With Delayed Graft Function
Sponsor: University of Maryland, Baltimore
Terminated
The trial was stopped because of slow recruitment.
A PHASE4 clinical study on Delayed Graft Function and Kidney Transplant, this trial is terminated or withdrawn. The trial is conducted by University of Maryland, Baltimore and has accumulated 12 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Apr 2022 [monthly]
Terminated PHASE4
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
-
Dec 2019 — Jan 2021 [monthly]
Terminated PHASE4
-
Sep 2019 — Dec 2019 [monthly]
Terminated PHASE4
-
Jun 2018 — Sep 2019 [monthly]
Terminated PHASE4
-
Apr 2018 — Jun 2018 [monthly]
Terminated PHASE4
Status: Unknown Status → Terminated
-
Feb 2017 — Apr 2018 [monthly]
Unknown Status PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE4
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Maryland, Baltimore
- Wyeth is now a wholly owned subsidiary of Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .